S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Pure Storage stock fumbles for a rare buying opportunity
Regime Change At Federal Reserve? (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
Regime Change At Federal Reserve? (Ad)
Bitcoin has surpassed $41,000 for the first time since April 2022. What's behind the price surge?
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Pure Storage stock fumbles for a rare buying opportunity
Regime Change At Federal Reserve? (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
Regime Change At Federal Reserve? (Ad)
Bitcoin has surpassed $41,000 for the first time since April 2022. What's behind the price surge?
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Pure Storage stock fumbles for a rare buying opportunity
Regime Change At Federal Reserve? (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
Regime Change At Federal Reserve? (Ad)
Bitcoin has surpassed $41,000 for the first time since April 2022. What's behind the price surge?
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Pure Storage stock fumbles for a rare buying opportunity
Regime Change At Federal Reserve? (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
Regime Change At Federal Reserve? (Ad)
Bitcoin has surpassed $41,000 for the first time since April 2022. What's behind the price surge?
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts

Ironwood Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IRWD)

$10.53
+0.23 (+2.23%)
(As of 12/4/2023 ET)
Compare
Today's Range
$10.16
$10.62
50-Day Range
$8.79
$10.53
52-Week Range
$8.07
$12.66
Volume
2.29 million shs
Average Volume
2.29 million shs
Market Capitalization
$1.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.67

Ironwood Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
96.3% Upside
$20.67 Price Target
Short Interest
Bearish
11.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.94
Upright™ Environmental Score
News Sentiment
-0.10mentions of Ironwood Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$300,119 Bought Last Quarter
Proj. Earnings Growth
-40.19%
From $1.07 to $0.64 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

605th out of 952 stocks

Pharmaceutical Preparations Industry

285th out of 434 stocks


IRWD stock logo

About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

IRWD Stock Price History

IRWD Stock News Headlines

U.S. Military Defense Fails Without Vanadium?
The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply.
Q3 2023 Ironwood Pharmaceuticals Inc Earnings Call
U.S. Military Defense Fails Without Vanadium?
The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply.
Implied Volatility Surging for Ironwood (IRWD) Stock Options
See More Headlines
Receive IRWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/15/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IRWD
CUSIP
46333X10
Employees
219
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.67
High Stock Price Target
$22.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+96.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$175.07 million
Net Margins
-220.24%
Pretax Margin
-209.57%

Debt

Sales & Book Value

Annual Sales
$410.60 million
Cash Flow
$1.17 per share
Book Value
$4.24 per share

Miscellaneous

Free Float
135,676,000
Market Cap
$1.64 billion
Optionable
Optionable
Beta
0.84
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives















IRWD Stock Analysis - Frequently Asked Questions

Should I buy or sell Ironwood Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IRWD shares.
View IRWD analyst ratings
or view top-rated stocks.

What is Ironwood Pharmaceuticals' stock price target for 2024?

2 brokers have issued 1 year target prices for Ironwood Pharmaceuticals' shares. Their IRWD share price targets range from $19.00 to $22.00. On average, they predict the company's stock price to reach $20.67 in the next year. This suggests a possible upside of 96.3% from the stock's current price.
View analysts price targets for IRWD
or view top-rated stocks among Wall Street analysts.

How have IRWD shares performed in 2023?

Ironwood Pharmaceuticals' stock was trading at $12.39 at the start of the year. Since then, IRWD stock has decreased by 15.0% and is now trading at $10.53.
View the best growth stocks for 2023 here
.

When is Ironwood Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our IRWD earnings forecast
.

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by $0.05. The biotechnology company had revenue of $113.74 million for the quarter, compared to the consensus estimate of $112.90 million. Ironwood Pharmaceuticals had a positive trailing twelve-month return on equity of 112.29% and a negative net margin of 220.24%. The firm's revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.28 EPS.

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $435.00 million-$450.00 million, compared to the consensus revenue estimate of $441.42 million.

What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO?

7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include LSV Asset Management (4.59%), Victory Capital Management Inc. (2.82%), Armistice Capital LLC (2.21%), Adage Capital Partners GP L.L.C. (1.58%), Jacobs Levy Equity Management Inc. (1.52%) and Jupiter Asset Management Ltd. (1.42%). Insiders that own company stock include Alexander J Denner, Andrew Davis, Jason Rickard, Julie Mchugh, Mark G Currie, Marla L Kessler, Michael Shetzline, Ronald Silver, Sravan Kumar Emany, Thomas A Mccourt and Timothy M O'reilly.
View institutional ownership trends
.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IRWD) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -